Talimogene Laherparepvec: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Talimogene Laherparepvec. Educational only — not medical advice.
Labeled uses
IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use : IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases.
Source: FDA labeling via NIH DailyMed (set 64ffb680…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.